Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibrosarcoma × pexidartinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Giant Cell Tumor of Tendon Sheath 6 Synovitis, Pigmented Villonodular 3 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Gastrointestinal Stromal Tumors 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stage I Prostate Adenocarcinoma 1 Solid Tumor 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neurofibrosarcoma 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Hemangiosarcoma 1 Glioblastoma 1 Colorectal Neoplasms 1 Advanced Solid Tumors 1

Interventions

Doxorubicin 15 Ifosfamide 10 Radiotherapy 5 selinexor 4 pazopanib 4 Filgrastim 4 pembrolizumab 3 pegfilgrastim 3 Sirolimus 3 Magnetic Resonance Spectroscopy 3 AZD 6244 3 fludarabine phosphate 2 brostallicin 2 X-Rays 2 Trabectedin 2 Specimen Handling 2 Sorafenib 2 Nivolumab 2 Imatinib Mesylate 2 Etoposide 2 Biopsy 2 thymoglobulin 1 temsirolimus 1 tazemetostat 1 sotigalimab 1 ribociclib 1 pexidartinib 1 perifosine 1 metarrestin 1 lorvotuzumab mertansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡